Legal teams at pharmaceutical and life-sciences groups approaching control transactions touching the 2025 OECD Merger Review Recommendation are increasingly using AI to draft regulatory-strategy memos on remedies hierarchy, generate transaction-committee briefings on divestiture-package design, and validate Section IV.3 remedies-priority language against the OECD text before remedy negotiations open with competition authorities.
The RLB Specialist Panel put a set of practitioner-grade questions on the 2025 OECD Merger Review Recommendation to two frontier AI models with web search active. Each question is prepared by the Panel based on the workflows that legal teams at pharmaceuticals firms actually use AI for under the OECD's 2025 revision of the Recommendation of the Council on Merger Review (OECD/LEGAL/0333). The Panel then binds every AI response to verbatim regulator-issued source text held as primary substrate.
On the 2025 OECD Merger Review Recommendation, the AI subjects returned a single hallucinated answer for legal teams at pharmaceuticals firms, in the form of Misattributed Cross-Jurisdictional Doctrine.
For legal teams at pharmaceuticals firms advising on cross-border merger transactions touching the 2025 OECD Merger Review Recommendation, citation accuracy on the operative architecture, on Section IV.3 remedies hierarchy, and on Section III.11.b failing firm defence is load-bearing in every authority-facing submission, every board memo, and every transactional document. A counterparty or competition authority who identifies a structural inflation, a misattributed sub-hierarchy, or a closed-cumulative-test framing on first reading calls the entire piece of advice into question.
The structural-architecture failure is the most directly visible: a board memo or regulator-facing submission that lists 'international co-operation' or 'monitoring' as operative RECOMMENDS sections is wrong on first reading. The Section IV.3 EU sub-hierarchy import is the most insidious failure, reading as authoritative because the EU framework is real, but presenting EU practice as OECD content imports the wrong normative baseline into the firm's remedy strategy.
The published Specialist Panel findings carry the following citation identifiers:
RLB-H-INT-OECD-OECD-MERGER-REVIEW-RECOMMENDATION-2025-Q002-Sonnet46 (Section IV.3 structural remedy priority order misattributed to EU practice)This is the consolidated view of findings. Click the Citation IDs or 'see details →' on any item for the full details for each finding.
When Legal teams at Pharmaceuticals firms ask AI tools to summarise the internal priority ordering within structural remedies under the OECD Recommendation, AI assistants we tested returned a three-tier hierarchy, fix-it-first divestitures, then commitments backed by an approved buyer pool and trustee mandate, then crown jewel or ring-fenced packages, sourced from EU merger-control enforcement practice rather than from the Recommendation itself. The Recommendation's Section IV.3 establishes a single preference: standalone-business divestitures are prioritised within the structural tier, with no timing-based sub-ordering.
A deal playbook, board paper, or internal guidance document built on the AI's version misrepresents the applicable multilateral standard and potentially mis-scopes the firm's remedy posture across every OECD-member-state filing where that document serves as the reference. The downstream cost is not regulatory penalty but mispriced deal risk: a remedy package designed around the wrong framework may require mid-negotiation restructuring, extending transaction timelines and increasing external counsel fees at the point of maximum exposure.
Every finding on this page compares an AI subject's account of the rule against the regulator's verbatim text from the regulator's own portal. Both are linked. Each delta, its root causes, and impact analysis are documented and published with immutable Citation IDs.